COPD is a condition characterized by progressive airflow obstruction which is rather insensible to bronchodilators. The pathogenetic mechanisms of this disorder are multifaceted, encompassing pulmonary inflammation, small airway remodelling, emphysema and mucous hypersecretion. As our comprehension of the heterogeneous pathology of the disease has improved it has been recognized that the ongoing inflammatory process in COPD is correlated with the relentlessness of this condition. Therefore, the scientific interest has been directed in the development of new anti-inflammatory drugs targeting pulmonary inflammation. In this survey, we will try to evaluate current treatment options and the potential and efficacy of new treatment modalities.
Current Respiratory Medicine Reviews publishes frontier reviews on all the latest advances on respiratory diseases and its related areas e.g. pharmacology, pathogenesis, clinical care, and therapy. The journal's aim is to publish the highest quality review articles dedicated to clinical research in the field. The journal is essential reading for all researchers and clinicians in respiratory medicine.